Each year, the Institute partners with drug development and delivery experts around the world to bring free, informative seminars and training programs to the pharmaceutical industry, academia and regulators.
Space is limited - Register now!
July8The pharmaceutical industry continues to experience decreasing productivity and high levels of attrition. Inflation of molecule physicochemical properties and complexities in clinical trial protocols stand among the main reasons for these trends. The most successful companies can leverage different expertise, manage risks, and follow logical sequences of operations in an integrated manner to speed development. Hosted by the Catalent Applied Drug Delivery Institute, with the Department of Pharmaceutical Sciences (DISFARM), University of Milan, and Leads to Development, this webinar will focus on the key considerations for transitioning a molecule from discovery through clinical studies including molecule developability assessment, phase-appropriate formulation selection, integration of product development and clinical supply as well as regulatory requirements for advancing a developmental candidate to clinical trials. The Catalent Applied Drug Delivery Institute brings together pharmaceutical innovators, organizations, and academia to improve clinical outcomes, medication delivery profiles, patient adherence and treatment efficacy.
MORE
October2The Catalent Applied Drug Delivery Institute, Columbia Lab-to-Market Accelerator Network and the Translational Therapeutics Accelerator (TRx) will be organizing an upcoming event focused on key considerations for transitioning a molecule from discovery to phase 1 readiness.
MOREApril4This event will focus on key considerations for transitioning a molecule from discovery to phase 1 readiness including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of clinical supply services solutions to meet protocol, clinical site and patient needs.
MORE
March28The event will bring together world-leading experts on biological drug development and delivery from across industry and academia to present leading edge biological research and key industry topics from cell line development through commercialization.
MORE
March12This one-of-a-kind symposium will focus on key considerations for transitioning a molecule from discovery to clinic including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of patient focus design principles. The agenda is designed to be highly interactive with activities designed for the audience to work in teams to apply the principles from the presentations and ample time for networking.
MOREFebruary13This one-of-a-kind symposium will focus on key considerations for transitioning a molecule from discovery to clinic including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of patient focus design principles. The agenda is designed to be highly interactive with activities designed for the audience to work in teams to apply the principles from the presentations and ample time for networking.
MOREMay7Since the sequencing of the human genome nearly two decades ago, scientists have made numerous breakthroughs in understanding disease pathophysiology and developing molecules for “undruggable” targets. However, the pharmaceutical industry continues to experience decreasing productivity and high levels of attrition. One reason is that novel small molecule drugs have inflated physicochemical properties, which lead to low bioavailability and poor safety and efficacy profiles. Addressing these issues early and comprehensively can result in fewer problems in later development phases such as escalating timelines, costs, and regulatory issues. Leveraging the skills and experience of experts and integrating competencies can optimize the development pathway and enable drug candidates to reach their true potential. This event will focus on key considerations for transitioning a molecule from discovery to phase 1 readiness including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of patient focus design principles.
View DetailsNovember30Making the right choices is important in today’s R&D environment, especially considering the various pressures on developers such as time, resources, and funding. Short term thinking can lead to long term problems leading to missed timelines, escalating costs, and even regulatory issues in later phases. These factors can unfortunately contribute to non-optimal drug products unless they are addressed upfront by incorporating patient focused design principles to promote better drug performance and patient outcomes. This event will focus on a number of key considerations for developing the best small or large molecule drug product for patients: • Avoiding the biggest pitfalls in drug development • Addressing biopharmaceutical challenges • Incorporating patient considerations in designing a drug product • Latest trends and technologies for small and large molecule therapeutics Exclusively for JLABS residents – Meet with a Catalent expert: Attendees have the opportunity to discuss their projects and challenges and learn about potential solutions in a 1-on-1 setting with a Catalent formulation or biologics expert. This is a complimentary opportunity for all attendees. Advanced scheduling is requested. Please email Ronak Savla (ronak.savla@catalent.com) or Dan Peizer (dan.peizer@catalent.com).
MOREJune13Making the right choices is important in today’s R&D environment, especially considering the various pressures on developers such as time, resources, and funding. Short term thinking can lead to long term problems leading to missed timelines, escalating costs, and even regulatory issues in later phases. These factors can unfortunately contribute to non-optimal drug products unless they are addressed upfront by incorporating patient focused design principles to promote better drug performance and patient outcomes. This event will focus on a number of key considerations for developing the best small or large molecule drug product for patients: • Avoiding the biggest pitfalls in drug development • Addressing biopharmaceutical challenges such as low solubility • Incorporating patient considerations in designing a drug product • Latest trends and technologies for small and large molecule therapeutics Exclusively for JLABS residents – you can pre-register for a complimentary 1-on-1 consultation with a formulation expert to discuss your biggest current development challenges
View Details
February21The Non-Invasive Delivery of Macromolecules Conference will feature preeminent experts presenting on how to unlock the full therapeutic potential of biopharmaceuticals. Critically, this meeting will examine comparison of benefits and efficacy of non-invasive delivery approaches with parenteral methods. The program will foster learning and provide a forum for academic and industrial scientists to fully explore oral, transdermal, nasal, pulmonary, and ocular deliveries in one fully integrated conference.
Learn More & Register Today
April7This half-day session will present current thinking and trends in patient-centric design from a number of different industry perspectives, followed by group Q&A as time permits.
Learn More & Register TodayMarch24The Catalent Institute experts from Catalent Pharma Solutions, Ionis Pharmaceuticals, Pure MHC, Sevion, UC Berkeley, and Applied Molecular Transport will present on the latest developments in development of biological therapies and delivery.
Learn More & Register TodayOctober26Innovator Challenges to Optimizing Drug Design. Cornell Stamoran, VP, Corporate Strategy & Founder Catalent Applied Drug Development Institute and Industry guests. (Invited: Merck, Pfizer, & Novo Nordisk). Followed by the latest developments in enabling technologies: Lipid Based Delivery Systems, Particle Size Engineering, Amorphous Systems, Solid State Optimization.
View DetailsSeptember17The Catalent Institute and drug delivery experts from Catalent Pharma Solutions, BASF, Hovione and Qualicaps & Colorcon presented bioavailability challenges, patient-centric drug design & innovative technologies.
View Details
June24Academic and industry drug delivery experts shared the current challenges and opportunities with alternate routes of delivering large molecules orally, via inhalation, using microneedles and minimally invasive methods for ocular delivery. Two case studies for oral delivery of large molecules were also shared during the 60 minutes webinar.
View DetailsApril30The Catalent Institute and drug delivery experts from Catalent Pharma Solutions, 3M, Saarland University and Lipp Life Sciences presented topics surrounding bioavailability enhancement, advanced drug delivery methods and patient centric drug design. Participants had the opportunity to bring their toughest drug development challenges to discuss with the expert panel, have a tour of the 3M Innovation Center and network with other scientists from industry and academia.
VIEW DETAILSMarch12The Catalent Institute and noteworthy drug delivery experts from Catalent Pharma Solutions, Pfizer Inc., Liquidia Technologies, Dispersol, Rutgers University and Cloud Pharmaceuticals presents Advances in Drug Delivery & Design: The Patient Journey and Addressing Solubility & Bioavailability Challenges for Improved Outcomes. This event is designed to cater to Vice Presidents, Directors, Principal Scientists and Graduate Students joining us from leading pharmaceutical companies and universities.
VIEW DETAILSJanuary29Engaging academic and industrial expertise in non-invasive delivery of macromolecules. Recent advances in non-invasive delivery strategies provide a critical step to overcome the challenges of patient access and compliance that involve cold-chain, patient compliance, and efficacy issues. Multi-disciplinary partnerships between academics, which interface with industrial partners and clinical programs, are becoming an increasingly attractive mechanism to accelerate the identification and advancement of improved basic biological understanding into translational outcomes.
VIEW DETAILSNovember18The overarching theme of Pharma Integrates 2014 was Strategically Transforming Pharma Relationships. Through a series of engaging and interactive panel discussions, participants shared their thoughts and experiences on how to encourage greater collaboration among key stakeholders who shape the future of the Pharma industry. Catalent Experts presented "Reinventing the Pharmaceutical Business Model".
September10The Catalent Institute and noteworthy drug delivery experts from Catalent Pharma Solutions, St. John’s University, the University of Mississippi and Agere presented Advances in Drug Delivery – Optimal Bioavailability and Controlled Release for Improved Outcomes. Over 150 participants, including Vice Presidents, Directors, Principal Scientists and Graduate Students from leading pharmaceutical companies and universities, attended this lively interactive training session.
VIEW DETAILSJune23The Catalent Applied Drug Delivery Institute successfully launched the "Non-Invasive Macromolecule Drug Delivery Consortium" on Monday, June 23rd, 2014 in San Diego, CA. This exclusive one-day workshop welcomed scientists and experts focused on oral, pulmonary/nasel, transdermal or ocular drug delivery of large molecules. This consortium was created by the Catalent Applied Drug Delivery Institute and is co-sponsored by Genentech, 3M, Takeda/Millennium and Allergan.
VIEW DETAILSJune12The Catalent Institute and world-class experts from 3M, Catalent Pharma Solutions, Agere and Xhale met at the 3M Innovation Center in St. Paul, Minnesota for “Innovation Showcase – Advanced Drug Delivery Approaches for Small and Large Molecules” a complimentary symposium and networking event focused on drug delivery challenges facing R&D teams today.
VIEW DETAILSMarch27The Catalent Institute and world-class experts from the University of Saarland, 3M, BASF, Catalent Pharma Solutions, Hovione, Agere and Formac Pharmaceuticals came together at the Novartis Campus in Basel, Switzerland for “Overcoming Bioavailability Challenges,” a complimentary training event focused on drug development and delivery challenges facing R&D teams today.
VIEW DETAILSJanuary27Catalent Institute Leader, Dr. Cornell Stamoran and other leading experts led a two-day panel discussion at DDP 2014 titled "Improved Patient Outcomes through Better Drug Design: Our Call to Action” and "Designing for Better Outcomes: Turning Concept into Practice."
VIEW DETAILSOctober3The Catalent Institute partnered with world-class expert instructors from University of Bath, 3M, BASF, Catalent Pharma Solutions and Formac Pharmaceuticals at the Royal Society of Chemistry in London for “Overcoming Bioavailability Challenges,” an interactive educational event focused on drug development challenges facing R&D teams today.
VIEW DETAILSSeptember20Catalent Institute Experts presented, “Don’t Leave Money on the Table” a collaborative product development discussion.
VIEW DETAILSJune12The Catalent Institute and experts from BEND, BASF, NJIT and FORMAC Pharmaceuticals hosted this inaugural educational event. More than 100 registrants, ranging from Vice Presidents, Directors and Principal Scientists to Graduate Students from leading pharmaceutical companies and universities, registered to attend this live interactive training event.
VIEW DETAILS